Questions & explanations
1. Compare in vivo CRISPR editing for liver versus eye diseases.
Both aim to correct genetic mutations in specific tissues. For the liver, delivery is often via intravenous injection of lipid nanoparticles or AAV, which naturally target the liver. The liver is large and well-perfused, so many cells can be reached. For the eye, delivery is by direct injection into the eye, which is small and isolated, requiring less vector. The eye is also immune-privileged, reducing immune reactions. However, the liver can regenerate, so edited cells may be lost over time, while eye cells are non-dividing, so edits are permanent. Both approaches have shown promise in clinical trials, but liver editing faces more challenges with immune responses and off-target effects.
2. Compare CRISPR gene therapy for sickle cell disease and beta-thalassemia.
Both diseases are caused by mutations in hemoglobin genes, and both can be treated by boosting fetal hemoglobin using CRISPR to disable BCL11A. The editing process is similar: collect stem cells, edit ex vivo, and infuse back. However, the underlying mutations differ: sickle cell has a single point mutation in beta-globin, while beta-thalassemia has various mutations that reduce beta-globin. The goal for both is to increase fetal hemoglobin to compensate. Clinical outcomes are also similar: many patients become transfusion-independent. But sickle cell patients may also experience reduced pain crises. Both therapies are among the first CRISPR-based treatments to reach patients.
3. What safety concerns are there with using CRISPR in CAR-T cell engineering?
One concern is off-target edits, where CRISPR cuts unintended DNA sites, potentially causing harmful mutations. This is especially risky when making multiple edits. Another concern is that disrupting the TCR might create T cells with unpredictable behavior. Also, if the CAR gene is inserted incorrectly, it might cause uncontrolled T cell growth or leukemia. To address these, researchers use high-fidelity Cas9 enzymes and thoroughly screen edited cells for off-target effects. Additionally, including a safety switch, like a suicide gene, can allow elimination of the CAR-T cells if they become dangerous. Clinical trials monitor patients closely for long-term side effects.
4. Why is ice formation a problem when freezing organs?
When water inside cells freezes, it forms sharp ice crystals that can tear cell membranes and destroy the cell structure. This damage is irreversible and makes the organ unusable for transplantation. Even slow freezing causes ice to form between cells, which also harms tissues. To avoid this, scientists use cryoprotectants, which are chemicals that lower the freezing point and help water become a glass-like solid instead of ice. This process is called vitrification. However, current cryoprotectants can be toxic to cells, especially at the high concentrations needed for large organs. So balancing ice prevention with chemical toxicity is a major challenge.
5. How is CRISPR used to engineer CAR-T cells?
CAR-T cells are T cells that are modified to express a chimeric antigen receptor (CAR) that recognizes cancer cells. CRISPR can be used to insert the CAR gene into a specific location in the T cell genome, such as the T cell receptor (TCR) locus. This ensures the CAR is expressed under the control of the TCR promoter, leading to more natural regulation. Additionally, CRISPR can knock out the endogenous TCR to prevent graft-versus-host disease when using donor cells. It can also knock out immune checkpoint genes like PD-1 to enhance anti-tumor activity. These edits are done ex vivo, and the engineered cells are then expanded and infused into the patient.
6. What is CRISPR gene therapy for sickle cell disease?
Sickle cell disease is caused by a mutation in the gene for hemoglobin, the protein that carries oxygen in red blood cells. CRISPR gene therapy aims to fix this by editing the patient's own blood stem cells outside the body (ex vivo). One approach uses CRISPR to disable a gene called BCL11A, which normally turns off fetal hemoglobin production. Reactivating fetal hemoglobin can compensate for the defective adult hemoglobin. The edited stem cells are then infused back into the patient, where they produce healthy red blood cells. Early clinical trials have shown promising results, with patients producing fetal hemoglobin and having fewer painful crises.
7. Compare natural quorum sensing with synthetic quorum sensing in terms of components.
Natural quorum sensing uses native proteins and autoinducers that bacteria already have. Synthetic quorum sensing often uses parts from different bacteria or even engineered parts. For example, a synthetic system might use the LuxI protein from Vibrio fischeri to make an autoinducer, and the LuxR protein to detect it, but these are put into a different bacterium like E. coli. Synthetic systems can also use orthogonal signals that do not cross-talk with the host's natural quorum sensing. This allows precise control without interference. Natural systems are evolved for the bacterium's own benefit, while synthetic systems are designed for human purposes.
8. What is an mRNA-based personalized vaccine for autoimmune diseases?
An mRNA-based personalized vaccine uses a patient's own genetic information to create a treatment that teaches the immune system to stop attacking the body's own tissues. In autoimmune diseases, the immune system mistakenly attacks healthy cells. The vaccine contains mRNA instructions for making a protein that helps the immune system recognize and tolerate those cells. This approach is personalized because the mRNA is designed based on the patient's specific disease markers. It aims to reduce inflammation and damage without suppressing the whole immune system. Early research shows promise for conditions like multiple sclerosis and type 1 diabetes.
9. How is CRISPR being developed to treat inherited liver diseases?
Inherited liver diseases like hemophilia or familial hypercholesterolemia are caused by mutations in liver genes. In vivo CRISPR aims to correct these mutations directly in liver cells. Delivery is often done using adeno-associated virus (AAV) vectors or lipid nanoparticles that carry the CRISPR components to the liver. For example, in hemophilia B, CRISPR can be used to insert a correct copy of the factor IX gene into the liver genome, allowing the liver to produce the clotting factor. Animal studies have shown long-term correction, and human trials are beginning. Challenges include immune responses to AAV and ensuring enough cells are edited.
10. What challenges exist for in vivo CRISPR editing in muscle diseases like Duchenne muscular dystrophy?
Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, which is very large. In vivo CRISPR aims to restore dystrophin by deleting or skipping mutated exons. Challenges include delivering CRISPR to all muscles throughout the body, as muscles are widespread and hard to reach. AAV vectors can deliver CRISPR, but they are limited by the size of the gene and may cause immune responses. Also, muscle cells are long-lived and do not divide much, so editing must be efficient and permanent. Despite these hurdles, animal studies have shown partial restoration of dystrophin and improved muscle function. Human trials are ongoing.
11. Give an example of CRISPR being used to treat inherited blindness.
Inherited blindness like Leber congenital amaurosis (LCA) is caused by mutations in genes like CEP290, which are essential for vision. In vivo CRISPR therapy for LCA involves injecting CRISPR components directly into the eye, specifically into the retina. The delivery is done using AAV vectors that target photoreceptor cells. In a clinical trial, patients received an AAV carrying a CRISPR system designed to correct a specific mutation in CEP290. Early results showed some improvement in vision, with no serious side effects. The eye is a good target for in vivo editing because it is small and immune-privileged, meaning less immune reaction.
12. How does ex vivo CRISPR editing work for genetic blood disorders?
Ex vivo means editing cells outside the body. For blood disorders, doctors first collect a patient's blood stem cells from bone marrow or blood. In the lab, they use CRISPR to edit the cells, for example, to disable BCL11A to boost fetal hemoglobin. After editing, they check that the cells are correctly modified and free of harmful off-target changes. The patient then receives chemotherapy to destroy their remaining faulty stem cells. Finally, the edited stem cells are infused back into the patient, where they travel to the bone marrow and start producing healthy blood cells. This approach has been used successfully in clinical trials.